Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Ziprasidone belongs to a group of medicines that work by blocking certain chemical signals in the brain—specifically dopamine and serotonin receptors. This action is thought to be why it helps reduce symptoms of schizophrenia and related psychotic conditions. It's approved in Australia for treating schizophrenia, preventing relapse in those conditions, and for short-term treatment of acute manic or mixed episodes in bipolar I disorder.
The medication stays active in the body for roughly 7 to 10 hours after a dose, though this varies between individuals—some people clear it in as little as 3 hours, others take up to 18 hours. Your family member's liver processes ziprasidone mainly through an enzyme called CYP3A4, with some contribution from another enzyme, CYP1A2. This matters because other medications that affect these enzymes could change how ziprasidone works in their system.
Side effects you might notice include sedation, dizziness, or headache. Some people develop akathisia—a restless, uncomfortable urge to move—or other movement-related effects grouped under the term 'extrapyramidal disorder.' These can include stiffness, tremor, or unusual movements.
More serious risks exist, though they don't affect everyone. Tardive dyskinesia involves involuntary movements, often of the face or tongue, that can persist even after stopping the medication. Neuroleptic malignant syndrome is a rare but dangerous reaction causing high fever, muscle rigidity, and confusion. Ziprasidone can also prolong the heart's QT interval—the time it takes for the heart to reset between beats—which in some cases leads to a dangerous heart rhythm called torsade de pointes. For this reason, the medication shouldn't be used in people with recent heart attack, uncontrolled heart failure, existing QT-interval problems, congenital long QT syndrome, or those taking certain other medications that also prolong the QT interval. Serotonin syndrome and a severe allergic reaction called DRESS are other serious but less common risks.
If you notice new or worsening movement problems, fever with muscle stiffness, heart palpitations, or signs of severe allergic reaction, seek medical attention promptly.
Acute mania or mixed episodes Clinical criteria: The condition must be associated with bipolar I disorder, AND The treatment must be as monotherapy, AND The treatment must be limited to up to 6 months per episode.
“However, it has been proposed that this drug's efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism.”
“The mean terminal phase half-life after multiple dosing in normal volunteers and schizophrenic patients is between 6 and10 hours, with a range of individual values from 3 to 18 hours.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Ziprasidone is an indole-derivative antipsychotic proposed to exert its therapeutic effect through combined dopamine type 2 (D₂) and serotonin type 2 (5-HT₂) antagonism. It is indicated for the treatment of schizophrenia, related psychoses, prevention of relapse, maintenance of clinical improvement during continuation therapy, and as monotherapy for short-term treatment of acute manic or mixed episodes associated with bipolar I disorder.
The mean terminal half-life ranges from 6 to 10 hours after multiple dosing, with individual variation from 3 to 18 hours. Ziprasidone is metabolised primarily via CYP3A4, with some contribution from CYP1A2. Common adverse effects include sedation, akathisia, dizziness, extrapyramidal disorder, and headache. Serious adverse effects encompass neuroleptic malignant syndrome, torsade de pointes, serotonin syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), and tardive dyskinesia.
Ziprasidone is contraindicated in known hypersensitivity to any ingredient, recent acute myocardial infarction, uncompensated heart failure, and conditions with potential to increase the QT interval, including QT-interval prolongation or history thereof, congenital long QT syndrome, concomitant use with other QT-prolonging drugs, and arrhythmias treated with class IA or III antiarrhythmic agents.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro studies indicate that CYP3A4 is the major cytochrome catalysing the oxidative metabolism of ziprasidone with some potential contribution from CYP1A2.”